Aceragen

Illustration connected puzzle pieces with the acronym MA

Biotech

Idera buys rare-disease-focused Aceragen in all-stock deal

What caught Idera’s attention was Aceragen’s lead assets, including ACG-701, which is set to enter phase 2 trials later this year.

James Waldron Sep 29, 2022 7:30am

Handshake

Aceragen bags Enzyvant drug and $35M, plots fast path to market

May 3, 2021 8:10am